DrugPatentWatch Database Preview
Crisaborole - Generic Drug Details
What are the generic sources for crisaborole and what is the scope of freedom to operate?
Crisaborole
is the generic ingredient in one branded drug marketed by Anacor Pharms Inc and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Crisaborole has one hundred and thirty patent family members in twenty-four countries.
There are three drug master file entries for crisaborole. One supplier is listed for this compound.
Summary for crisaborole
| International Patents: | 130 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 3 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 67 |
| Clinical Trials: | 14 |
| Patent Applications: | 40 |
| DailyMed Link: | crisaborole at DailyMed |
Recent Clinical Trials for crisaborole
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pfizer | Phase 3 |
| Ann & Robert H Lurie Children's Hospital of Chicago | Phase 4 |
| Johns Hopkins University | Phase 4 |
Pharmacology for crisaborole
| Drug Class | Phosphodiesterase 4 Inhibitor |
| Mechanism of Action | Phosphodiesterase 4 Inhibitors |
Synonyms for crisaborole
| 1073669-75-6 |
| 1187189-21-4 |
| 4-((1-HYDROXY-1,3-DIHYDROBENZO-[C][1,2]OXABOROL-5-YL)OXY)BENZONITRILE |
| 4-((1-Hydroxy-1,3-dihydrobenzo(c)(1,2)oxaborol-6-yl)oxy)benzonitrile |
| 4-((1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)oxy)benzonitrile |
| 4-(1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yloxy)benzonitrile |
| 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile |
| 4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzonitrile |
| 4-[(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]benzonitrile |
| 5-(4-cyanophenoxy)-1-hydroxy-2,1-benzoxaborole |
| 5-(4-cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole |
| 5098AC |
| 906673-24-3 |
| ABP001114 |
| AC-30331 |
| AK102641 |
| AKOS016005425 |
| AN 2728 |
| AN-2728 |
| AN2728 |
| ANW-65536 |
| API0013781 |
| AX8234180 |
| BC245091 |
| BCP08677 |
| BDBM50277665 |
| Benzonitrile, 4-((1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy)- |
| Benzonitrile, 4-[(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]- |
| C14H10BNO3 |
| CHEBI:134677 |
| CHEMBL484785 |
| compound 5b [PMID: 19303290] |
| Crisaborole (USAN/INN) |
| Crisaborole [USAN:INN] |
| Crisaborole topical ointment 2% |
| Crisaborole, >=98% (HPLC) |
| Crisaborole(AN-2728) |
| CS-1057 |
| CTK8C0958 |
| D10873 |
| DB-078771 |
| DB05219 |
| DTXSID10238231 |
| Eucrisa |
| Eucrisa (TN) |
| EX-A1087 |
| FT-0767999 |
| GTPL9151 |
| HY-10978 |
| KB-40872 |
| KS-0000063U |
| MolPort-023-332-548 |
| NCGC00345792-01 |
| NCGC00345792-02 |
| Q2R47HGR7P |
| SB16802 |
| SCHEMBL595261 |
| ST24042710 |
| TC-154281 |
| UNII-Q2R47HGR7P |
| USZAGAREISWJDP-UHFFFAOYSA-N |
| W-5676 |
| ZINC169748244 |
US Patents and Regulatory Information for crisaborole
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Anacor Pharms Inc | EUCRISA | crisaborole | OINTMENT;TOPICAL | 207695-001 | Dec 14, 2016 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for crisaborole
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 102532180 | Start Trial |
| China | 101914109 | Start Trial |
| Japan | 6046876 | Start Trial |
| Slovenia | 2343304 | Start Trial |
| South Africa | 201506944 | Start Trial |
| South Korea | 20150113219 | Start Trial |
| European Patent Office | 2987796 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.